CCCC Q2 2022 Earnings — C4 Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CCCCC4 Therapeutics, Inc.

$243M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+41.4% YoY

Gross Profit

-$17M-126.4% margin

Operating Income

-$27M-197.9% margin

Net Income

-$27M-198.1% margin

EPS (Diluted)

$-0.56

QoQ Revenue Growth

+80.7%

Cash Flow

Operating Cash Flow

-$22M

Free Cash Flow

-$23M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$492M

Total Liabilities

$148M

Stockholders' Equity

$345M

Cash & Equivalents

$57M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$10M	+41.4%
Gross Profit	-$17M	-$14M	-29.5%
Operating Income	-$27M	-$22M	-23.8%
Net Income	-$27M	-$23M	-21.4%